


Harnessing the power of amnion for the treatment of chronic wounds



Dermacyte[®]
Regenerative Wound Care

A Powerful Regenerative Wound Matrix to Support Acute and Chronic Wound Closure

Dermacyte® products are derived from human postpartum amniotic tissues that have been processed to retain native extracellular matrix cytokines, growth factors, and collagen to support tissue remodeling, improving patient outcomes and treatment comfort.



Easy to Use

Ready for Application

- Dehydrated for easy application with no refrigeration
- No preparation time required for thawing or soaking—reducing operative time

Easy to Handle

- Conforms to wound bed and naturally hydrates in place
- Superior handling and optimal bioabsorption properties

Improved Patient Experience

Use as protective wound barrier to provide an antimicrobial, growth factor rich healing environment

Promotes native tissue repair by minimizing fibrosis, reducing inflammation, and maximizing patient comfort

Simple Wound Monitoring

Routine dressing changes, wound cleansing, and Dermacyte® reapplication allows for easy assessment of wound closure.

Clinical Applications

Dermacyte® products are versatile coverings and void fillers that may be applied to various hard-to-heal wounds, including:

- Diabetic foot ulcers
- Venous stasis ulcers
- Burns
- Decubitus / Pressure Ulcers
- Surgical incisions
- Other dermal defects and wounds




Dermacyte
Amniotic Wound Care **Matrix**

Dermacyte® – A Unique Bioactive Wound Covering

Scaffolds:

The special structure and biological viability of amniotic membrane is ideal in tissue engineering. The extracellular matrix components of the basement membrane creates a natural scaffold for cell attachment.¹



Signals:

Amniotic tissue is rich in cytokines, growth factors, and stem cells that play a role in improved healing and regeneration and decreased immunogenicity.²



Cells:

Sufficient cues to allow for cell attachment and proliferation are properties of dehydrated amnion. Soluble factors secreted by human dermal fibroblasts cultured on amnion enhanced both endothelial cell and keratinocyte survival and endothelial cell migration in a wound closure assay.³



PRODUCT OFFERING

Actual sizes:

2cm
x
2cm

2cm
x
4cm

4cm
x
4cm

Dermacyte® Matrix

SIZE	PRODUCT CODE
2 x 2 cm ²	AM-D10022
2 x 4 cm ²	AM-D10024
4 x 4 cm ²	AM-D10044
4 x 6 cm ²	AM-D10046
4 x 8 cm ²	AM-D10048

Committed to Patient Safety

- All tissues are recovered and processed by a U.S. FDA registered and AATB accredited tissue bank
- A Licensed Medical Director confirms product eligibility through donor screening and testing records, and final culturing and sterility testing is confirmed prior to lot release

For information related to Dermacyte insurance benefit verifications, assistance or claims appeal assistance, please contact our **Reimbursement Support Line.**

Phone: (919) 921-8105 Ext 119
Fax: (919) 267-3753
Email: info@merakris.com



Merakris Therapeutics Inc

800 Park Offices Drive, Suite 3322

Research Triangle Park, NC 27709

919.921.8105

www.merakris.com

FDA Establishment Identifier

(FEI): 3013695841

Dermacyte® is regulated by the U.S. FDA under 21 CFR Part 1271 and Section 361 of the Public Health Service Act. Dermacyte® is a registered trademark of Merakris Therapeutics Inc. Copyright © 2021 Merakris Therapeutics.

References:

1. Niknejad H et al. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater.* 2008 Apr 29;15:88-99.
2. Haugh A et al. Amnion membrane in diabetic foot wounds: a meta-analysis. *Plastic and Reconstr Surg Glob Open.* 2017 Apr; 5:e1302.
3. Guo et al. Modulation of cell attachment, proliferation, and angiogenesis by decellularized, dehydrated human amniotic membrane in in vitro models. *Wounds.* 2017 Jan;29(1):28-38.